Market research
1093.HK CSPC Pharmaceutical Group Limited
HK HKD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 105B
- P/E ratio
- 12.09
- Analyst target
- 12.3109
- Dividend yield
- 3.0%
- Beta
- 0.75
Profile
Company facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- HK1093012172
- Market cap
- 105B
- P/E ratio
- 12.09
- Analyst target
- 12.3109
- Dividend yield
- 3.0%
- Beta
- 0.75
About
About CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1093.HK discussion.
5 years, 5 months ago
CSPC Pharmaceutical Group Limited is currently in a long term uptrend where the price is trading 12.7% above its 200 day moving average.
From a valuation standpoint, the stock is 96.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.0.
CSPC Pharmaceutical Group Limited's total revenue rose by 7.2% to $6B since the same quarter in the previous year.
Its net income has increased by 81.8% to $2B since the same quarter in the previous year.
Finally, its free cash flow grew by 46.2% to $2B since the same quarter in the previous year.
Based on the above factors, CSPC Pharmaceutical Group Limited gets an overall score of 5/5.